Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial-Reference-Cited by-同舟云学术

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

Published:2014-06 Issue:6 Volume:14 Page:459-467
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Grinsztejn Beatriz,De Castro Nathalie,Arnold Vincent,Veloso Valdiléa G,Morgado Mariza,Pilotto José Henrique,Brites Carlos,Madruga José Valdez,Barcellos Nêmora Tregnago,Santos Breno Riegel,Vorsatz Carla,Fagard Catherine,Santini-Oliveira Marilia,Patey Olivier,Delaugerre Constance,Chêne Geneviève,Molina Jean-Michel

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference20 articles.

1. Integration of antiretroviral therapy with tuberculosis treatment;Abdool Karim;N Engl J Med,2011

2. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis;Blanc;N Engl J Med,2011

3. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis;Havlir;N Engl J Med,2011

4. An updated systematic reviewand meta-analysis on the treatment of active tuberculosis in patients with HIV infection;Ahmad Khan;Clin Infect Dis,2012

5. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources;Lawn;Lancet Infect Dis,2010

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people with HIV with profound immunosuppression;HIV Medicine;2024-08-12

2. Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis;Viruses;2024-03-23

3. Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics;Expert Review of Clinical Pharmacology;2024-02-14

4. Tuberculosis–HIV co-infection in an era of complex, rapid new drug development;AIDS;2023-10-01

5. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial;The Lancet HIV;2023-07